Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Transcription profiling of stage UICC II vs UICC III colorectal cancer

ABSTRACT: Analyze differential expression between stage UICC II and UICC III colorectal cancer

ORGANISM(S): Homo sapiens

SUBMITTER: Manuela Hummel

PROVIDER: E-MEXP-383 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III.

Groene Joern J Mansmann Ulrich U Meister Reinhard R Staub Eike E Roepcke Stefan S Heinze Maya M Klaman Irina I Brümmendorf Thomas T Hermann Klaus K Loddenkemper Christoph C Pilarsky Christian C Mann Benno B Adams Hans-Peter HP Buhr Heinz Johannes HJ Rosenthal André A

International journal of cancer 20061001 8

UICC stage II and III colorectal cancers (CRC) differ fundamentally in prognosis and therapeutic concepts. To analyze differential gene expression between both stages and to establish a relationship between molecular background and clinical presentation, tumor material from 36 unselected consecutive patients presenting with sporadic CRC, 18 UICC stage II and 18 UICC stage III, were laser microdissected to separate epithelial tumor cells. Gene expression levels were measured using U133A Affymetri ...[more]

PMID: 16721809

Similar Datasets

Project description:Wiskott-Aldrich syndrome (WAS) predisposes patients to leukemia and lymphoma. WAS is caused by mutations in the protein WASP which impair its interaction with the WIPF1 protein. Here, we aim to identify a module of WIPF1-coexpressed genes and to assess its use as a prognostic signature for colorectal cancer, glioma, and breast cancer patients. Two public colorectal cancer microarray data sets were used for discovery and validation of the WIPF1 co-expression module. Based on expression of the WIPF1 signature, we classified more than 400 additional tumors with microarray data from our own experiments or from publicly available data sets according to their WIPF1 signature expression. This allowed us to separate patient populations for colorectal cancers, breast cancers, and gliomas for which clinical characteristics like survival times and times to relapse were analyzed. Groups of colorectal cancer, breast cancer, and glioma patients with low expression of the WIPF1 co-expression module generally had a favorable prognosis. In addition, the majority of WIPF1 signature genes are individually correlated with disease outcome in different studies. Literature gene network analysis revealed that among WIPF1 co-expressed genes known direct transcriptional targets of c-myc, ESR1 and p53 are enriched. The mean expression profile of WIPF1 signature genes is correlated with the profile of a proliferation signature. The WIPF1 signature is the first microarray-based prognostic expression signature primarily developed for colorectal cancer that is instrumental in other tumor types: low expression of the WIPF1 module is associated with better prognosis. We used microarrays for the validation of a WIPF1 co-expression module which was developed on two publically available datasets. Keywords: disease state analysis For the generation of our own microarray data set, 62 CRC patients undergoing elective standard oncological resection at the Department of General, Vascular and Thoracic Surgery, Campus Benjamin Franklin, Charité, were prospectively recruited.

Dataset Information

Transcription profiling of stage UICC II vs UICC III colorectal cancer

Publications

Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure